Do Social Media and Blogs Have a Positive Impact on Patient Quality of Life?

Article

Last week, well-known Canadian blogger Derek Miller's final blog entry was posted on his site, penmachine.com. Miller, who died on May 3 at the age of 41, was diagnosed with stage IV metastatic colorectal cancer in 2007.

Last week, well-known Canadian blogger Derek Miller's final blog entry was posted on his site, penmachine.com. Miller, who died on May 3 at the age of 41, was diagnosed with stage IV metastatic colorectal cancer in 2007.

"Here it is. I'm dead, and this is my last post to my blog. In advance, I asked that once my body finally shut down from the punishments of my cancer, then my family and friends publish this prepared message I wrote the first part of the process of turning this from an active website to an archive," read the post.

In this era of social media and blogging, online interaction often surpasses time spent with friends and family in person. For many, it has also created an outlet for expression that perhaps didn't exist for them before.

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.